ADC Therapeutics disclosed top-line results from the Phase 3 LOTIS-5 confirmatory trial of Zynlonta (loncastuximab tesirine) plus rituximab in relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company reported statistical significance on progression-free survival but no overall survival benefit, with an elevated treatment-arm death imbalance—27 deaths versus nine in controls—casting uncertainty over the path to full approval. Although ADC described deaths as treatment-emergent adverse events, analysts flagged that the safety signal could complicate physician and regulator acceptance in a potential earlier-line utilization scenario. The update illustrates how confirmatory datasets are increasingly decisive in determining label expansion for accelerated-approval ADCs. The immediate market reaction highlighted investor sensitivity to mortality outcomes beyond conventional efficacy endpoints, reinforcing the importance of mature benefit-risk packages before confirmatory readouts land.